Status:
UNKNOWN
The Immunodynamic Effect of Radiotherapy in Prostate Cancer Patients.
Lead Sponsor:
Regina Elena Cancer Institute
Collaborating Sponsors:
Paola Nisticò
Iole Cordone
Conditions:
Prostatic Neoplasm
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
Radiotherapy has an important role in the treatment of prostate cancer both as curative treatment and postoperative or salvage ones. Several studies demonstrated a significant reduction of lymphocytes...
Eligibility Criteria
Inclusion
- Histologically documented prostatic cancer
- Indication to perform radiotherapy treatment
- Age over 18 years
- Informed consent
Exclusion
- Hematological diseases
- Autoimmune diseases
- Previous neoplasias
- Prior chemotherapy or other therapies that may have violated the hematopoietic organs
- Patient's refusal to undergo periodic blood samples
Key Trial Info
Start Date :
February 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04774133
Start Date
February 14 2019
End Date
January 1 2022
Last Update
March 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCSS Regina Elena
Roma, Italy, 00144